Table 1.
Patients, Disease, and Transplantation Characteristics
| Variable | Total N (%) | |||
|---|---|---|---|---|
| Number of patients / centers | 273 / 95 | |||
| Gender | F: 141 (52) | |||
| Recipient age | Total N (%) | 55-60 | 61-65 | 66+ |
| Year of HCT | ||||
| 2001-2003 | 29 (11) | 12 (10) | 16 (15) | 1 (2) |
| 2004-2007 | 57 (21) | 28 (23) | 21 (20) | 8 (18) |
| 2008-2011 | 187 (68) | 83 (67) | 68 (65) | 36 (80) |
| Karnofsky score | ||||
| <=80 | 101 (37) | 45 (37) | 34 (32) | 22 (49) |
| 90-100 | 153 (56) | 69 (56) | 66 (63) | 18 (40) |
| Missing | 19 (7) | 9 (7) | 5 (5) | 5 (11) |
| HCT-CI | ||||
| 0 | 71 (26) | 29 (24) | 29 (28) | 13 (29) |
| 1 + | 117 (43) | 54 (44) | 39 (37) | 24 (53) |
| Earlier than 2007 | 73 (27) | 33 (27) | 33 (31) | 7 (16) |
| Missing | 12 (4) | 7 (6) | 4 (4) | 1 (2) |
| Disease status | ||||
| CR1 | 195 (71) | 92 (75) | 69 (66) | 34 (76) |
| >=CR2 | 47 (17) | 22 (18) | 19 (18) | 6 (13) |
| PIF/Rel | 29 (11) | 8 (7) | 17 (16) | 4 (9) |
| Missing | 2 (<1) | 1 (<1) | 0 | 1 (2) |
| Time from diagnosis to HCT | ||||
| <6 months | 123 (45) | 61 (50) | 43 (41) | 19 (42) |
| 6 - 12 months | 86 (32) | 30 (24) | 38 (36) | 18 (40) |
| >12 months | 64 (23) | 32 (26) | 24 (23) | 8 (18) |
| Median (range) | 7 (2-121) | 6 (2-85) | 7 (3-121) | 7 (4-43) |
| Conditioning regimen | ||||
| Low-dose TBI based (2Gy) | ||||
| TBI+Flu | 84 (31) | 35 (32) | 32 (29) | 17 (32) |
| TBI+other | 8 (3) | 2 (2) | 5 (5) | 1 (2) |
| Alkylating agent based | ||||
| Bu (≤8mg/kg po ≤6.4mg/kg IV) + Flu | 62 (23) | 27 (21) | 24 (23) | 11 (30) |
| Flu+Mel (<150mg/m2) | 80 (29) | 44 (34) | 30 (28) | 6 (16) |
| Cy+Flu | 15 (5) | 6 (5) | 7 (7) | 2 (5) |
| Other Alkylating agents | 13 (5) | 4 (3) | 5 (5) | 4 (11) |
| Other regimen | 11 (4) | 5 (4) | 2 (4) | 4 (4) |
| In-vivo T-cell depletion (ATG or campath) | ||||
| No | 189 (69) | 87 (71) | 69 (66) | 33 (73) |
| Yes | 83 (30) | 36 (29) | 35 (33) | 12 (27) |
| Missing | 1 (<1) | 0 | 1 (<1) | 0 |
| Graft type | ||||
| Bone marrow | 19 (7) | 7 (6) | 10 (10) | 2 (4) |
| Peripheral blood | 233 (85) | 105 (85) | 88 (84) | 40 (89) |
| Single UCB | 4 (1) | 2 (2) | 2 (2) | 0 |
| Double UCB | 17 (6) | 9 (7) | 5 (5) | 3 (7) |
| Type of donor | ||||
| Matched sibling | 92 (34) | 46 (37) | 36 (34) | 10 (22) |
| MUD | 104 (38) | 39 (32) | 41 (39) | 24 (53) |
| UCB | 21 (8) | 11 (9) | 7 (7) | 3 (7) |
| Other& | 56 (21) | 27 (22) | 21 (20) | 8 (18) |
| Prior fungal infections* | ||||
| No | 108 (91) | 47 (90) | 45 (94) | 16 (84) |
| Yes | 10 (8) | 4 (8) | 3 (6) | 3 (16) |
| Missing | 1 (<1) | 1 (2) | 0 | 0 |
| Cytogenetics* | ||||
| t(9;22) present | 59 (50) | 31 (60) | 20 (42) | 8 (42) |
| t(9;22) absent | 33 (28) | 13 (25) | 14 (29) | 6 (32) |
| Missing | 27 (23) | 8 (15) | 14 (29) | 5 (26) |
| Extramedullary disease at diagnosis* | ||||
| No | 104 (87) | 46 (88) | 42 (88) | 16 (84) |
| Yes | 14 (12) | 6 (12) | 6 (13) | 2 (11) |
| Missing | 1 (<1) | 0 | 0 | 1 (5) |
| Time to achieve CR1* | ||||
| <=8 weeks | 48 (40) | 21 (40) | 21 (44) | 6 (32) |
| >8 weeks | 51 (43) | 22 (42) | 19 (40) | 10 (53) |
| N/A, CR1 not achieved | 5 (4) | 2 (4) | 2 (4) | 1 (5) |
| Missing | 15 (13) | 7 (13) | 6 (13) | 2 (11) |
| Median (range), weeks | 8 (2-57) | 8 (2-41) | 7 (2-57) | 11 (2-33) |
| Median follow-up of survivors (range), months | 49 (3-145) | 73 (3-145) | 61 (13-118) | 62 (20-74) |
*
Data limited to nested cohort of 119 subjects (55 centers)
Abbreviations: F: Female, HCT-CI: Hematopoietic Stem Cell Transplant-Comorbidity Index, CR:Complete Remission, TBI: Total Body Irradiation, Flu: Fludarabine, Bu: Busulfaran, CsA: Cyclosporine, MTX:Methotrexate, MMF: mycophenolate mofetil, MUD: matched unrelated donor, UCB: Umbilical Cord Blood, ATG: Anti-Thymocyte Globulin
&
mismatched unrelated donor and mismatched related(haplo=9)